{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:49:40Z","timestamp":1772642980736,"version":"3.50.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Although neoadjuvant therapy followed by surgery is the standard treatment for resectable locally advanced esophageal carcinoma, heterogeneity exists in neoadjuvant regimens within real-world practice. This study characterizes lymph node recurrence (LNR) patterns and compares LNR risk factors across different neoadjuvant approaches to better elucidate therapeutic efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were collected from esophageal carcinoma (EC) patients who underwent surgery following neoadjuvant therapy between January 2018 and December 2023. Neoadjuvant regimens included neoadjuvant chemotherapy (NCT), neoadjuvant chemoimmunotherapy (NICT), and neoadjuvant chemoradiotherapy (NCRT)\/neoadjuvant chemoradiotherapy combined with immunotherapy (NCRT\/NICRT). Regional lymph node stations were defined per the Japanese Esophageal Society (JES) criteria. Cox proportional hazards models were used to identify factors associated with LNR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>This study enrolled 658 patients, including 195 with postoperative LNR. Among all EC cases, the most frequent recurrence sites were No. 106tb (5.5%), No. 109 (5.5%), and No. 104 (8.7%). The most frequent recurrence sites in the NCT group were No. 104 (10.0%) and No. 106tb (7.9%); in the NICT group, No. 104 (8.2%) was the most common; in the NCRT\/NICRT group, No. 101 (7.0%) and No. 104 (7.0%) demonstrated the highest recurrence rates. In upper thoracic EC, No. 101, No. 104, and No. 105 were common recurrence sites with metastasis rates exceeding 5%; in mid-thoracic EC, No. 104 (11.9%) showed the highest recurrence frequency; in lower thoracic and gastroesophageal junction EC, No. 104 (5.5%) and No. 16 (4.8%) were frequent recurrence locations. Lymph node dissection count and ypT and\/or ypN stage correlated with recurrence risk across neoadjuvant regimens. Adjuvant radiotherapy demonstrated lower lymph node metastasis rates in the tracheoesophageal groove and upper mediastinal LNR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The tracheoesophageal groove and supraclavicular lymph nodes represent common recurrence sites in neoadjuvant therapy and upper thoracic EC. Lower thoracic and gastroesophageal junction EC require vigilance for the risk of supraclavicular nodal metastasis. Lymph node yield and T\/N stages correlate with recurrence risk.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1668649","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T04:15:54Z","timestamp":1760415354000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of lymph node recurrence patterns and risk factors in locally advanced esophageal carcinoma following neoadjuvant therapy"],"prefix":"10.3389","volume":"15","author":[{"given":"Yingxin","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zixuan","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puchang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pudong","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yatian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(23)00211-6","article-title":"National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data","volume":"8","author":"Qi","year":"2023","journal-title":"Lancet Public Health"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2019.03.04","article-title":"Incidence and mortality of esophagus cancer in China, 2008-2012","volume":"31","author":"He","year":"2019","journal-title":"Chin J Cancer Res"},{"key":"B4","article-title":"Clinical evaluation of the esophageal lymph flow system based on RI uptake of dissected regional lymph nodes following lymphoscintigraphy","volume":"87","author":"Tanabe","year":"1986","journal-title":"Nihon Geka Gakkai Zasshi"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.08.002","article-title":"Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010","volume":"138","author":"Liu","year":"2020","journal-title":"Eur J Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0140-6736(24)00745-1","article-title":"Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial","volume":"404","author":"Kato","year":"2024","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.953229","article-title":"Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy","volume":"13","author":"Qiao","year":"2022","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1031171","article-title":"Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"106680","DOI":"10.1016\/j.ijsu.2022.106680","article-title":"Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE)","volume":"103","author":"Yan","year":"2022","journal-title":"Int J Surg"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000000978","article-title":"Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study)","volume":"110","author":"Yang","year":"2024","journal-title":"Int J Surg"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-14534-9","article-title":"A comparison of clinicopathologic outcomes and patterns of lymphatic spread across neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy, and neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma","volume":"31","author":"Tian","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000001242","article-title":"Accurate location describe and management of lymph node recurrence after esophagectomy for thoracic esophageal squamous cell carcinoma: a retrospective cohort study","volume":"110","author":"Zhao","year":"2024","journal-title":"Int J Surg"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.21037\/acs.2017.03.14","article-title":"8th edition AJCC\/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice","volume":"6","author":"Rice","year":"2017","journal-title":"Ann Cardiothorac Surg"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10388-024-01054-y","article-title":"Japanese classification of esophageal cancer, 12th edition: part I","volume":"21","author":"Mine","year":"2024","journal-title":"Esophagus"},{"key":"B17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.21037\/atm-22-513","article-title":"Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001)","volume":"10","author":"Shang","year":"2022","journal-title":"Ann Transl Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005830","article-title":"Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial","volume":"11","author":"Chen","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-14809-1","article-title":"Long-term survival and recurrence patterns in locally advanced esophageal squamous cell carcinoma patients with pathologic complete response after neoadjuvant chemotherapy followed by surgery","volume":"31","author":"Wu","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jtcvs.2023.08.056","article-title":"Two-year outcomes of clinical N2\u20133 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study","volume":"167","author":"Yang","year":"2024","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1200\/JCO.20.03614","article-title":"Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial","volume":"39","author":"Eyck","year":"2021","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2022.08.009","article-title":"Prognostic value of recurrence pattern in locally advanced esophageal squamous cell carcinoma: Results from the phase III trial NEOCRTEC5010","volume":"165","author":"Chen","year":"2023","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B23","doi-asserted-by":"publisher","first-page":"zrab022","DOI":"10.1093\/dote\/doab052.681","article-title":"Pattern of recurrence in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer","volume":"5","author":"de Jongh","year":"2021","journal-title":"BJS Open"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s10388-022-00977-8","article-title":"Significance of dissection in each regional lymph-node station of esophageal cancer based on efficacy index and recurrence patterns after curative esophagectomy","volume":"20","author":"Kanemura","year":"2023","journal-title":"Esophagus"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000001557","article-title":"The prevalence of overall and initial lymph node metastases in clinical T1N0 thoracic esophageal cancer: from the results of JCOG0502, a prospective multicenter study","volume":"264","author":"Akutsu","year":"2016","journal-title":"Ann Surg"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008229","article-title":"Short-course neoadjuvant radiotherapy combined with chemotherapy and toripalimab for locally advanced esophageal squamous cell carcinoma (SCALE-1): a single-arm phase Ib clinical trial","volume":"12","author":"Jiang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000375391","article-title":"Postoperative intensity-modulated radiotherapy improved survival in lymph node-positive or stage III thoracic esophageal squamous cell carcinoma","volume":"38","author":"Zhang","year":"2015","journal-title":"Oncol Res Treat"},{"key":"B28","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s00262-024-03826-y","article-title":"Adjuvant chemoradiotherapy plus pembrolizumab for locally advanced esophageal squamous cell carcinoma with high risk of recurrence following neoadjuvant chemoradiotherapy: a single-arm phase II study","volume":"73","author":"Guo","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.3390\/biomedicines10112989","article-title":"Adjuvant chemoradiotherapy associated with improved overall survival in resected esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy in intensity-modulated radiotherapy era","volume":"10","author":"Yap","year":"2022","journal-title":"Biomedicines"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S104221","article-title":"Postoperative radiation in esophageal squamous cell carcinoma and target volume delineation","volume":"9","author":"Zhu","year":"2016","journal-title":"Onco Targets Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.663679","article-title":"Mapping of cervical and upper mediastinal lymph node recurrence for guiding clinical target delineation of postoperative radiotherapy in thoracic esophageal squamous cell carcinoma","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13014-022-01987-7","article-title":"Postoperative lymphatic recurrence distribution and delineation of the radiation field in lower thoracic squamous cell esophageal carcinomas: a real-world study","volume":"17","author":"Du","year":"2022","journal-title":"Radiat Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34417","article-title":"Incidence and management of esophageal cancer recurrence to regional lymph nodes after curative esophagectomy","volume":"152","author":"Boerner","year":"2023","journal-title":"Int J Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-11625-x","article-title":"Selective lymphadenectomy for salvage esophagectomy in patients with esophageal squamous cell carcinoma","volume":"29","author":"Mayanagi","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000004798","article-title":"Impact of lymph node dissection on survival after neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: from the results of NEOCRTEC5010, a randomized multicenter study","volume":"277","author":"Guo","year":"2023","journal-title":"Ann Surg"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3181904f3c","article-title":"Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes","volume":"248","author":"Peyre","year":"2008","journal-title":"Ann Surg"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1668649\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T04:15:55Z","timestamp":1760415355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1668649\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":36,"alternative-id":["10.3389\/fonc.2025.1668649"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1668649","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"article-number":"1668649"}}